SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    RiesLAG EM, KosaryCL, HankeyBF, et al. (eds.). SEER Cancer Statistics Review, 1975–2002. Bethesda, MD: National Cancer Institute, 2005.
  • 2
    Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol. 2003; 170(6 Pt 2): S2125; discussion S26–27.
  • 3
    Fowler FJJr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA. 2000; 283: 32173222.
  • 4
    Alibhai SM, Krahn MD, Cohen MM, Fleshner NE, Tomlinson GA, Naglie G. Is there age bias in the treatment of localized prostate carcinoma? Cancer. 2004; 100: 7281.
  • 5
    Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence — SEER 13 Regs Public-Use, Nov 2004 Sub (1973–2002 varying), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.
  • 6
    Surveillance, Epidemiology, and End Results (SEER) Program Web site. Data quality. Available at: http://seer.cancer.gov/about/quality.html. Accessed May 6, 2005.
  • 7
    Piercy C VHV, Muir C. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization, 1990.
  • 8
    Tewari A, Horninger W, Pelzer AE, et al. Factors contributing to the racial differences in prostate cancer mortality. BJU Int. 2005; 96: 12471252.
  • 9
    R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing, 2005.
  • 10
    Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999; 94: 496509.
  • 11
    Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993; 88: 400409.
  • 12
    Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16: 11411154.
  • 13
    Bill-Axelson A, Holmberg L, Ruutu M, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2005; 352: 19771984.
  • 14
    Mostofi FK, Sesterhenn I, Sobin LH. Histological typing of prostate tumours. Geneva: World Health Organization, 1980.
  • 15
    Alexianu M, Weiss GH. Radical prostatectomy versus brachytherapy for early-stage prostate cancer. J Endourol. 2000; 14: 325328.
  • 16
    Jo Y, Junichi H, Tomohiro F, Yoshinari I, Masato F. Radical prostatectomy versus high-dose rate brachytherapy for prostate cancer: effects on health-related quality of life. BJU Int. 2005; 96: 4347.
  • 17
    Sharkey J, Cantor A, Solc Z, et al. Brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer. Curr Urol Rep. 2002; 3: 250257.
  • 18
    Sharkey J, Cantor A, Solc Z, et al. 103Pd brachytherapy versus radical prostatectomy in patients with clinically localized prostate cancer: a 12-year experience from a single group practice. Brachytherapy. 2005; 4: 3444.
  • 19
    Horwitz EM, Thames HD, Kuban DA, et al. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. J Urol. 2005; 173: 797802.
  • 20
    Horwitz EM, Vicini FA, Ziaja EL, Dmuchowski CF, Stromberg JS, Martinez AA. The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. Int J Radiat Oncol Biol Phys. 1998; 41: 267272.
  • 21
    Kuban D, Thames H, Levy L, et al. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: can one size fit all? Int J Radiat Oncol Biol Phys. 2005; 61: 409414.
  • 22
    Ray ME, Thames HD, Levy LB, et al. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2006; 64: 11401150.
  • 23
    Thames H, Kuban D, Levy L, et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys. 2003; 57: 929943.
  • 24
    Zelefsky MJ, Ben-Porat L, Scher HI, et al. Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer. J Clin Oncol. 2005; 23: 826831.
  • 25
    Vicini FA, Vargas C, Abner A, Kestin L, Horwitz E, Martinez A. Limitations in the use of serum prostate specific antigen levels to monitor patients after treatment for prostate cancer. J Urol. 2005; 173: 14561462.
  • 26
    Albertsen PC, Walters S, Hanley JA. A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995. J Urol. 2000; 163: 519523.
  • 27
    Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining cause of death in prostate cancer: are death certificates valid? J Natl Cancer Inst. 2001; 93: 18221823.
  • 28
    National Comprehensive Cancer Network (NCCN). Prostate Cancer Early Detection. v. 2.2005. Jenkintown, PA: National Comprehensive Cancer Network, 2005.
  • 29
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2005. CA Cancer J Clin. 2005; 55: 3144; quiz 55–36.
  • 30
    Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2006. CA Cancer J Clin. 2006; 56: 1125.
  • 31
    Albertsen PC, Hanley JA, Fine J. 20-Year outcomes following conservative management of clinically localized prostate cancer. JAMA. 2005; 293: 20952101.
  • 32
    Walsh PC. Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol. 2000; 163: 18021807.
  • 33
    Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol. 2004; 22: 21412149.
  • 34
    Alibhai SM, Klotz LH. A systematic review of randomized trials in localized prostate cancer. Can J Urol. 2004; 11: 21102117.
  • 35
    Adolfsson J, Steineck G, Hedlund PO. Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology. 1997; 50: 722726.
  • 36
    Chodak GW, Thisted RA, Gerber GS, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994; 330: 242248.
  • 37
    Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA. 2004; 291: 27132719.
  • 38
    Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997; 277: 467471.
  • 39
    Braga-Basaria M, Muller DC, Carducci MA, Dobs AS, Basaria S. Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy. Int J Impot Res. 2006; 18: 494498.
  • 40
    Joudi FN, Konety BR. The impact of provider volume on outcomes from urological cancer therapy. J Urol. 2005; 174: 432438.
  • 41
    Spencer BA, Steinberg M, Malin J, Adams J, Litwin MS. Quality-of-care indicators for early-stage prostate cancer. J Clin Oncol. 2003; 21: 19281936.
  • 42
    Cancer Statistics Branch SP. Bethesda, MD: SEER Program Code Manual, 1998.
  • 43
    Chan TY, Partin AW, Walsh PC, Epstein JI. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology. 2000; 56: 823827.
  • 44
    D'Amico AV, Moul J, Carroll PR, Sun L, Lubeck D, Chen M-H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol. 2003; 21: 21632172.
  • 45
    Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Biochemical outcome for hormone-naive patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology. 2002; 60: 98103.
  • 46
    Grimm PD, Blasko JC, Sylvester JE, Meier RM, Cavanagh W. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys. 2001; 51: 3140.